Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
4
×
boston top stories
deals
4
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
startups
boston
clinical trials
fda
investing
ipo
vc
480 biomedical
acetylon pharmaceuticals
acute myeloid leukemia
alx oncology
ambys medicines
arsenal medical
autoimmune diseases
azacitidine
berkeley lights
beta-thalassemia
biotech ipos
bob langer
cancer drugs
cancer immunotherapy
cd47
cell therapy
chronic kidney disease
chronic rhinosinusitis
constellation pharmaceuticals
covid-19
dacogen
decitabine
What
biotech
4
×
new
4
×
developing
ipo
medicines
raised
research
startup
therapeutics
aiming
aims
ambys
approach
arrival
based
big
called
companies
company
control
days
deadly
deal
debut
debuted
debuts
diseases
drugs
epigenetic
epigenetics
field
flagship’s
formed
future
hasn’t
industry
ipos
late
launch
life
Language
unset
Current search:
biotech
×
new
×
deals
×
" boston blog main "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?